NYSE:ZTS
Zoetis Inc.
A global leader in animal health delivering innovative vaccines and therapeutics that drive growth across livestock, companion, and food-producing animal markets.
Key Metrics
Investment Thesis
Bull Case
Investors may favor Zoetis due to its proven track record of organic growth, driven by a robust pipeline of new products that command premium pricing power in a defensive sector. The company's strong free cash flow generation supports consistent dividend payments and share buybacks, providing attractive total return potential even during broader market volatility.
Bear Case
Concerns regarding the high valuation multiples relative to peers could deter value-oriented investors looking for higher yield or lower entry points. Additionally, the substantial long-term debt of $9.04B and other current liabilities require careful monitoring as interest rates fluctuate or economic conditions tighten, potentially impacting financial flexibility.
About Zoetis Inc.
Zoetis Inc. (ZTS) is a global leader in animal health, specializing in the discovery, development, and commercialization of products that improve the health and welfare of livestock, companion animals, and food-producing animals worldwide. The company serves veterinarians, farmers, and pet owners through a portfolio of vaccines, therapeutics, and diagnostics. With robust cash flow generation and a strong balance sheet, Zoetis maintains its position as a premier player in the animal health sector.
Analysis
Management Discussion
Zoetis demonstrated consistent financial strength with revenue growing from $8.08B in 2022 to $9.47B in 2025, reflecting successful product launches and market expansion. Net income steadily increased over the same period, reaching $2.67B, while operating cash flow of $2.90B highlights the company's ability to generate liquidity for reinvestment and shareholder returns despite significant capital expenditures.
Industry Overview
The global animal health industry is experiencing steady growth driven by increasing pet ownership, rising protein demand, and greater focus on food safety and sustainability. As a market leader, Zoetis operates in an environment where innovation and regulatory compliance are paramount, offering stable long-term prospects amidst evolving agricultural and veterinary landscapes.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $8.08B | $8.54B | $9.26B | $9.47B |
| Cost of Revenue | $2.45B | $2.56B | $2.72B | $2.67B |
| Gross Profit | $5.63B | $5.98B | $6.54B | $6.80B |
| Operating Expenses | $2.97B | $3.05B | $3.40B | $3.44B |
| Operating Income | $2.66B | $2.94B | $3.13B | $3.36B |
| G&A | $2.01B | $2.15B | $2.32B | $2.38B |
| Stock-Based Comp | $62.0M | $60.0M | $74.0M | $83.0M |
| D&A | $465.0M | $491.0M | $497.0M | $487.0M |
| Depreciation | $272.0M | $306.0M | $327.0M | $330.0M |
| Amortization | $193.0M | $185.0M | $170.0M | $157.0M |
| Other OpEx | $961.0M | $896.0M | $1.09B | $1.06B |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Interest Expense | $221.0M | $239.0M | $225.0M | $222.0M |
| Pre-Tax Income | $2.66B | $2.94B | $3.13B | $3.36B |
| Income Tax | $545.0M | $596.0M | $637.0M | $687.0M |
| Continuing Ops | $2.11B | $2.34B | $2.50B | $2.67B |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $2.11B | $2.34B | $2.50B | $2.67B |
| Minority Interest | $-3.0M | $-4.0M | $10.0M | $0 |
| Net to Common | $2.11B | $2.34B | $2.49B | $2.67B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $7.51B | $6.34B | $5.99B | $6.77B |
| Accounts Receivable | $1.22B | $1.30B | $1.32B | $1.59B |
| Inventory | $2.35B | $2.56B | $2.31B | $2.43B |
| Other Current Assets | $3.95B | $2.48B | $2.36B | $2.75B |
| Long-Term Assets | $7.42B | $7.94B | $8.25B | $8.70B |
| PP&E (Net) | $2.75B | $3.20B | $3.39B | $3.68B |
| Intangibles | $1.38B | $1.34B | $1.13B | $998.0M |
| Goodwill | $2.75B | $2.76B | $2.72B | $2.77B |
| Operating Leases | $220.0M | $230.0M | $219.0M | $288.0M |
| Other LT Assets | $320.0M | $412.0M | $790.0M | $965.0M |
| Total Assets | $14.93B | $14.29B | $14.24B | $15.47B |
| Current Liabilities | $3.17B | $1.89B | $3.41B | $2.23B |
| Accounts Payable | $405.0M | $411.0M | $433.0M | $487.0M |
| Current Debt | $1.35B | $0 | $1.35B | $0 |
| Current Leases | $43.0M | $48.0M | $51.0M | $52.0M |
| Other Current Liab | $513.0M | $549.0M | $608.0M | $612.0M |
| Long-Term Liabilities | $7.36B | $7.41B | $6.05B | $9.90B |
| Long-Term Debt | $6.55B | $6.56B | $5.22B | $9.04B |
| LT Operating Leases | $186.0M | $188.0M | $174.0M | $196.0M |
| Other LT Liab | $359.0M | $383.0M | $389.0M | $387.0M |
| Total Liabilities | $10.52B | $9.29B | $9.47B | $12.14B |
| Shareholders' Equity | $4.40B | $4.99B | $4.77B | $3.33B |
| Paid-In Capital | $1.09B | $1.13B | $1.18B | $1.10B |
| Retained Earnings | $8.67B | $10.29B | $11.97B | $13.74B |
| AOCI | $-817.0M | $-839.0M | $-940.0M | $-834.0M |
| Treasury Stock | $4.54B | $5.60B | $7.45B | $10.69B |
| Total L&E | $14.93B | $14.29B | $14.24B | $15.47B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $2.11B | $2.34B | $2.50B | $2.67B |
| Non-Cash Adjustments | $-676.0M | $-591.0M | $280.0M | $-550.0M |
| Working Capital Changes | $477.0M | $604.0M | $177.0M | $781.0M |
| Cash from Operations | $1.91B | $2.35B | $2.95B | $2.90B |
| Capital Expenditures | $586.0M | $732.0M | $655.0M | $621.0M |
| Cash from Investing | $-883.0M | $-777.0M | $-315.0M | $-748.0M |
| Debt Repayments | $0 | $1.35B | $0 | $1.35B |
| Share Buybacks | $1.59B | $1.09B | $1.86B | $3.23B |
| Cash from Financing | $-904.0M | $-3.11B | $-2.66B | $-1.87B |
| FX Effect | $-29.0M | $-7.0M | $-32.0M | $39.0M |
| Net Change in Cash | $96.0M | $-1.54B | $-54.0M | $325.0M |
| Beginning Cash | $3.48B | $3.58B | $2.04B | $1.99B |
| Ending Cash | $3.58B | $2.04B | $1.99B | $2.31B |
Frequently Asked Questions
How does Zoetis Inc. make money?
The company's revenue is primarily driven by three core segments: Companion Animal Health (vaccines and treatments for pets), Food Producing Animal Health (solutions for livestock like cattle and swine), and Livestock Health (specialized programs for poultry and other species). These segments are supported by a diversified portfolio of products including vaccines, pharmaceuticals, and diagnostic tools that address key diseases and nutritional needs.
What are the main risks for ZTS?
Regulatory changes or delays in approval processes for new animal health products could impact future revenue streams and growth trajectories. Emerging diseases or shifts in consumer sentiment regarding antibiotic use and food safety may alter market dynamics and demand patterns. High R&D costs and the potential for failed clinical trials pose ongoing risks to profitability and capital allocation strategies.
What is ZTS's competitive advantage?
Zoetis benefits from an extensive proprietary pipeline of patented medicines and vaccines that create high barriers to entry for competitors. The company's deep distribution network allows for rapid deployment of products globally, while its strong R&D capabilities ensure a continuous flow of innovative solutions addressing emerging disease threats in animal populations.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.